



CURRICULUM VITAE of WANG LUYAO (luyaoben@126.com)

Name : Wang Luyao

Academic qualifications:

- 2006-2010 B. Med. School of Pharmacy, The South-central University for Nationalities, Wuhan, China.
- 2010-2013 M. Med. School of Pharmacy, The South-central University for Nationalities, Wuhan, China.

Previous academic position held:

- 2013-2015 Teaching Assistant Department of Science and Technology, Beijing Normal University-Hong Kong Baptist University United International College, Zhuhai, China.
- 2015-2017 Research Assistant Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR., China.

Present academic position:

- 2018 till now Ph.D. student Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR., China.

Previous relevant research work:

- Research area Aptamer-mediated tumor-targeted delivery of anti-cancer drugs.
Structural biology of aptamers in complex with their target proteins.

Publication Records:

Section A-Five most representative publications in the recent five years (* Corresponding Author)

1. Diangang Liu†, Qing Mei†, Weifang Long, Xiangluan Wan, Dingrong Wan, **Luyao Wang***. HPLC Fingerprint Analysis and Content Determination of Extract with Anticancer Activities of *Sedi linearis* Herba. *Pharmacognosy Journal* 2017; 9(2): 128-134.

Section B - Five representative publications beyond the recent five-year period with the latest publication entered first

2. Chao Liang†, Fangfei Li†, **Luyao Wang†**, Zongkang Zhang†, Chao Wang†, Bing He†, Jie Li, Zhihao Chen, A. B. Shaikh, Jin Liu, Xiaohao Wu, Songlin Peng, Lei Dang, Baosheng Guo, Xiaojuan He, D.W.T. Au, Hailong Zhu*, Baoting Zhang*, Aiping Lu*, Ge Zhang*. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. *Biomaterials* 2017; 147:68-85.
3. Fangfei Li†, Jun Lu†, Jin Liu†, Chao Liang†, Maolin Wang†, **Luyao Wang†**, Defang Li, Houzong Yao, Qiulong Zhang, Jia Wen, Zongkang Zhang, Jie Li, Quanxia Lv, Xiaojuan He, Guofen Chen, Feng Jiang, Shiguo Sun*, Baoting Zhang*, Aiping Lu*, Ge Zhang*. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. *Nature Communications* 2017; DOI: 10.1038/s41467-017-01565-6.

4. **Luyao Wang**†, Fangfei Li†, Lei Dang†, Chao Liang, Chao Wang, Bing He, Jin Liu, Defang Li, Xiaohao Wu, Xuegong Xu*, Aiping Lu*, Ge Zhang*. In Vivo Delivery Systems for Therapeutic Genome Editing. *International Journal of Molecular Sciences* 2016; 17(626): 1-19.
5. **Luyao Wang**†, Chao Liang†, Fangfei Li†, Daogang Guan, Xiaoqiu Wu, Xuekun Fu, Aiping Lu*, and Ge Zhang*. PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. *International Journal of Molecular Sciences* 2017; 18(2111): 1-16.
6. **Luyao Wang**, Qing Mei, Dingrong Wan*. Simultaneous determination by HPLC of quercetin and kaempferol in three *Sedum* medicinal plants harvested in different seasons. *Journal of Chromatography Science* 2014; 52(4): 334-338.

Award:

Wang Luyao. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. **Webster Jee Travel Award**. The 8th International Conference on Osteoporosis and Bone Research. Chong Qing, China, 2016.